{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:16:39Z","timestamp":1778868999635,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"REMD Biotherapeutics Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11095-026-04028-0","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:02:08Z","timestamp":1771549328000},"page":"1057-1070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic\/Pharmacodynamic Modeling of Volagidemab, a Glucagon Receptor Antagonist, in Healthy Chinese and US Subjects Following Single Subcutaneous Administration"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6434-5626","authenticated-orcid":false,"given":"Zihan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3402-365X","authenticated-orcid":false,"given":"Mingzhe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1164-4717","authenticated-orcid":false,"given":"Linxiu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-4998","authenticated-orcid":false,"given":"Jinwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4715-802X","authenticated-orcid":false,"given":"Feifei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1138-9638","authenticated-orcid":false,"given":"Haiyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3638-9444","authenticated-orcid":false,"given":"Hai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6694-4096","authenticated-orcid":false,"given":"Renyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-3051","authenticated-orcid":false,"given":"Hua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"2","key":"4028_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.mayocp.2017.12.003","volume":"93","author":"S Haedersdal","year":"2018","unstructured":"Haedersdal S, Lund A, Knop FK, Vilsboll T. The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin Proc. 2018;93(2):217\u201339.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"4028_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1152\/physrev.00025.2016","volume":"97","author":"TD Muller","year":"2017","unstructured":"Muller TD, Finan B, Clemmensen C, DiMarchi RD, Tschop MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721\u201366.","journal-title":"Physiol Rev"},{"issue":"7","key":"4028_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/BF00280887","volume":"28","author":"K Tan","year":"1985","unstructured":"Tan K, Tsiolakis D, Marks V. Effect of glucagon antibodies on plasma glucose, insulin and somatostatin in the fasting and fed rat. Diabetologia. 1985;28(7):435\u201340.","journal-title":"Diabetologia"},{"issue":"7","key":"4028_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/dmrr.2773","volume":"32","author":"JA Davidson","year":"2016","unstructured":"Davidson JA, Holland WL, Roth MG, Wang MY, Lee Y, Yu X, et al. Glucagon therapeutics: Dawn of a new era for diabetes care. Diabetes Metab Res Rev. 2016;32(7):660\u20135.","journal-title":"Diabetes Metab Res Rev"},{"issue":"10","key":"4028_CR5","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.2337\/diacare.26.10.2728","volume":"26","author":"R Derr","year":"2003","unstructured":"Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care. 2003;26(10):2728\u201333.","journal-title":"Diabetes Care"},{"issue":"11","key":"4028_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162255","volume":"8","author":"C Lubaczeuski","year":"2023","unstructured":"Lubaczeuski C, Bozadjieva-Kramer N, Louzada RA, Gittes GK, Leibowitz G, Bernal-Mizrachi E. Time-dependent effects of endogenous hyperglucagonemia on glucose homeostasis and hepatic glucagon action. JCI Insight. 2023;8(11): e162255.","journal-title":"JCI Insight."},{"issue":"10","key":"4028_CR7","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1038\/s41591-022-02011-x","volume":"28","author":"J Pettus","year":"2022","unstructured":"Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022;28(10):2092\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"4028_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI60016","volume":"122","author":"RH Unger","year":"2012","unstructured":"Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122(1):4\u201312.","journal-title":"J Clin Invest"},{"issue":"8","key":"4028_CR9","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1073\/pnas.1424934112","volume":"112","author":"MY Wang","year":"2015","unstructured":"Wang MY, Yan H, Shi Z, Evans MR, Yu X, Lee Y, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015;112(8):2503\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4028_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2337\/dc19-1328","volume":"43","author":"JH Pettus","year":"2020","unstructured":"Pettus JH, D\u2019Alessio D, Frias JP, Vajda EG, Pipkin JD, Rosenstock J, et al. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. Diabetes Care. 2020;43(1):161\u20138.","journal-title":"Diabetes Care"},{"issue":"11","key":"4028_CR11","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1111\/dom.13440","volume":"20","author":"DJ Kazierad","year":"2018","unstructured":"Kazierad DJ, Chidsey K, Somayaji VR, Bergman AJ, Calle RA. Efficacy and safety of the glucagon receptor antagonist PF-06291874: a 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy. Diabetes Obes Metab. 2018;20(11):2608\u201316.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4028_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/dom.13075","volume":"20","author":"A Kostic","year":"2018","unstructured":"Kostic A, King TA, Yang F, Chan KC, Yancopoulos GD, Gromada J, et al. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018;20(2):283\u201391.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"4028_CR13","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/dom.13202","volume":"20","author":"J Pettus","year":"2018","unstructured":"Pettus J, Reeds D, Cavaiola TS, Boeder S, Levin M, Tobin G, et al. Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2018;20(5):1302\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"4028_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/nyas.15262","volume":"1543","author":"D Dutta","year":"2025","unstructured":"Dutta D, Kamrul-Hasan ABM, Surana V, Singla R, Khandelwal D, Aggarwal S, et al. Efficacy and safety of the glucagon receptor antagonist volagidemab in type-1 diabetes: A systematic review and meta-analysis. Ann N Y Acad Sci. 2025;1543(1):94\u2013101.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"4028_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/jpet.108.147009","volume":"329","author":"H Yan","year":"2009","unstructured":"Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther. 2009;329(1):102\u201311.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4028_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/dom.15348","volume":"26","author":"C Cui","year":"2024","unstructured":"Cui C, Cao F, Kong II, Wu Q, Li F, Li H, et al. A model-informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong-acting dipeptidyl peptidase-4 inhibitor. Diabetes Obes Metab. 2024;26(2):592\u2013601.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"4028_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40262-022-01209-z","volume":"62","author":"L Song","year":"2023","unstructured":"Song L, Wang X, Sun J, Hu X, Li H, Hu P, et al. A model-informed approach to accelerate the clinical development of Janagliflozin, an innovative SGLT2 inhibitor. Clin Pharmacokinet. 2023;62(3):505\u201318.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4028_CR18","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1124\/dmd.119.086488","volume":"47","author":"A Datta-Mannan","year":"2019","unstructured":"Datta-Mannan A. Mechanisms influencing the pharmacokinetics and disposition of monoclonal antibodies and peptides. Drug Metab Dispos. 2019;47(10):1100\u201310.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"4028_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2512217","volume":"17","author":"SPH van den Berg","year":"2025","unstructured":"van den Berg SPH, Adolfsen PEA, Dorlo TPC, Rispens T. Does one model fit all mAbs? An evaluation of population pharmacokinetic models. MAbs. 2025;17(1):2512217.","journal-title":"MAbs"},{"issue":"1","key":"4028_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40262-018-0669-y","volume":"58","author":"JM Martinez","year":"2019","unstructured":"Martinez JM, Brunet A, Hurbin F, DiCioccio AT, Rauch C, Fabre D. Population pharmacokinetic analysis of alirocumab in healthy volunteers or hypercholesterolemic subjects using a Michaelis-Menten approximation of a target-mediated drug disposition model-support for a biologics license application submission: part I. Clin Pharmacokinet. 2019;58(1):101\u201313.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4028_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/bcpt.13202","volume":"125","author":"S Timmermann","year":"2019","unstructured":"Timmermann S, Hall A. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis. Basic Clin Pharmacol Toxicol. 2019;125(1):16\u201325.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"4028_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/jcph.1771","volume":"61","author":"MM Luo","year":"2021","unstructured":"Luo MM, Usmani SZ, Mateos MV, Nahi H, Chari A, San-Miguel J, et al. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. J Clin Pharmacol. 2021;61(5):614\u201327.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4028_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jcph.1698","volume":"61","author":"T Ide","year":"2021","unstructured":"Ide T, Roy A, Imai Y, Vezina HE. Model-based determination of elotuzumab pharmacokinetics in Japanese patients with multiple myeloma incorporating time-varying M protein. J Clin Pharmacol. 2021;61(1):64\u201373.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4028_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10928-016-9500-2","volume":"44","author":"LA Peletier","year":"2017","unstructured":"Peletier LA, de Winter W. Impact of saturable distribution in compartmental PK models: dynamics and practical use. J Pharmacokinet Pharmacodyn. 2017;44(1):1\u201316.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"4028_CR25","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/cells12111472","volume":"12","author":"N Ajmal","year":"2023","unstructured":"Ajmal N, Bogart MC, Khan P, Max-Harry IM, Nunemaker CS. Emerging anti-diabetic drugs for beta-cell protection in type 1 diabetes. Cells. 2023;12(11):1472.","journal-title":"Cells"},{"issue":"11","key":"4028_CR26","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cmet.2022.09.022","volume":"34","author":"R Sekar","year":"2022","unstructured":"Sekar R, Motzler K, Kwon Y, Novikoff A, Julg J, Najafi B, et al. Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes. Cell Metab. 2022;34(11):1824-42 e9.","journal-title":"Cell Metab."},{"issue":"10","key":"4028_CR27","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.2337\/db25-0209","volume":"74","author":"TM Cacciottolo","year":"2025","unstructured":"Cacciottolo TM, Lawler K, Mendez-Acevedo KM, Mendes de Oliveira E, Syanda A, Henning E, et al. Glucagon Receptor Deficiency Causes Early-Onset Hepatic Steatosis. Diabetes. 2025;74(10):1787\u2013801.","journal-title":"Diabetes."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04028-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04028-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04028-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:54:04Z","timestamp":1778867644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04028-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4028"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04028-0","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hai Yan and Renyu Xu are stockholde\/employee of REMD Biotherapeutics Inc. The other authors declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}